Logo

American Heart Association

  17
  0


Final ID: Sa4029

RUNX2, IBSP, and SPP1 as Key Molecular Nodes in Calcific Aortic Stenosis: Transcriptomic Diagnostics and Emerging Therapeutic Targets.

Abstract Body (Do not enter title and authors here): Calcific aortic stenosis (CAS) is the most common valvular disease in the elderly, with no approved pharmacological treatment to slow or reverse its progression. This study combined a systematic literature review (38 human-only studies, PRISMA criteria) with transcriptomic analysis of publicly available datasets (GSE51472 and GSE12644), including 35 human aortic valve samples (15 control, 15 calcified, 5 sclerotic). Differential expression was assessed using the Limma package, applying FDR correction (padj < 0.01) and fold change threshold (|FC| ≥ 1).
Key genes were identified based on significant overexpression and biological relevance. RUNX2, IBSP, and SPP1 emerged as central regulators linked to osteogenic transdifferentiation, immune modulation, and extracellular matrix remodeling. KEGG pathway analysis showed enrichment in ECM-receptor interaction, PI3K-Akt signaling. Coexpression and protein-protein interaction networks revealed strong functional clustering of these genes. ROC curve analysis yielded high diagnostic performance: AUC values were 0.79 (RUNX2), 0.65 (IBSP), and 0.75 (SPP1), indicating robust classification of diseased versus normal tissue. Expression levels rose progressively across control, calcified, and sclerotic valve samples.
Drug repurposing candidates were identified targeting these molecules. MEK inhibitors (trametinib, selumetinib) downregulate RUNX2 via MAPK/ERK pathway inhibition. Epigenetic modulators (vorinostat, valproic acid) could suppress RUNX2 transcriptionally. The integrin antagonist cilengitide blocks αvβ3, disrupting IBSP/SPP1-mediated signaling. While these agents are approved for oncology or neurology, their utility in valve calcification remains investigational.
In summary, this study highlights RUNX2, IBSP, and SPP1 as transcriptomic biomarkers and actionable therapeutic targets in CAS. Their expression profiles, biological roles, and druggability make them high-priority candidates for future diagnostic tools and targeted interventions in a disease currently reliant on surgical replacement.
  • Reyes Barragan, Irving  ( Instituto Politecnico Nacional , Mexico city , Mexico )
  • Author Disclosures:
    Irving reyes barragan: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Genomic Insights into Cardiac Valve and Aortic Disease

Saturday, 11/08/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts on this topic:
A Contemporary Machine Learning-Based Risk Stratification for Mortality and Hospitalization in Heart Failure with Preserved Ejection Fraction Using Multimodal Real-World Data

Fudim Marat, Weerts Jerremy, Patel Manesh, Balu Suresh, Hintze Bradley, Torres Francisco, Micsinai Balan Mariann, Rigolli Marzia, Kessler Paul, Touzot Maxime, Lund Lars, Van Empel Vanessa, Pradhan Aruna, Butler Javed, Zehnder Tobias, Sauty Benoit, Esposito Christian, Balazard Félix, Mayer Imke, Hallal Mohammad, Loiseau Nicolas

A drug target Mendelian randomization study of triglyceride lowering therapies for aortic stenosis

Ciofani Jonathan, Han Daniel, Gill Dipender, Rao Karan, Allahwala Usaid, Bhindi Ravinay

You have to be authorized to contact abstract author. Please, Login
Not Available